{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:30:33Z","timestamp":1794011433683,"version":"4.8.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>GPRC5D has emerged as a promising therapeutic target in relapsed\/refractory multiple myeloma (R\/R MM), particularly following progression after B-cell maturation antigen (BCMA)\u2013directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapies. RD118 is a novel CAR-T therapy incorporating a fully human single-domain antibody fragment targeting GPRC5D. In this phase 1 study, 18 R\/R patients (17 with MM and 1 with a history of primary plasma cell leukemia) received a single infusion of RD118 at 1.0 \u00d7 106, 2.0 \u00d7 106, or 3.0 \u00d7 106 CAR+ T cells per kg. At a median follow-up of 17.0 months, the overall response rate (ORR) was 94.4%, including 72.2% complete or stringent complete responses. Among the 7 patients previously exposed to BCMA-directed CAR-T therapy, ORR reached 85.7%. Median progression-free survival (PFS) was 18.2 months (95% confidence interval, 14.4 to not estimable), with 12-month PFS and overall survival rates of 82.1% and 93.3%, respectively. Cytokine release syndrome occurred in 88.9% of the patients, primarily grade 1 to 2. One patient developed grade 3 immune effector cell\u2013associated neurotoxicity, which resolved within 72 hours. No cerebellar toxicities or treatment-related deaths were reported. These findings support that RD118 is a highly effective and safe therapeutic option for heavily pretreated R\/R MM. This trial was registered at www.clinicaltrials.gov as #NCT05759793 and #NCT05219721.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030559","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:48:55Z","timestamp":1761076135000},"page":"513-519","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed\/refractory multiple myeloma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5060-2753","authenticated-orcid":false,"given":"Mengmeng","family":"Pan","sequence":"first","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1014-3745","authenticated-orcid":false,"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Jin","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Liu","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyan","family":"Ouyang","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqin","family":"Weng","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2054-6401","authenticated-orcid":false,"given":"Hongmei","family":"Yi","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"5Nanjing IASO Biotechnology Co, Ltd, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Cao","sequence":"additional","affiliation":[{"name":"5Nanjing IASO Biotechnology Co, Ltd, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Li","sequence":"additional","affiliation":[{"name":"5Nanjing IASO Biotechnology Co, Ltd, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"5Nanjing IASO Biotechnology Co, Ltd, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7133","authenticated-orcid":false,"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-5437","authenticated-orcid":false,"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2026012911211594200_bib1","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026012911211594200_bib2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026012911211594200_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"18","key":"2026012911211594200_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"2026012911211594200_bib5","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026012911211594200_bib6","doi-asserted-by":"crossref","first-page":"1433774","DOI":"10.3389\/fimmu.2024.1433774","article-title":"Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy","volume":"15","author":"Fu","year":"2024","journal-title":"Front Immunol"},{"issue":"13","key":"2026012911211594200_bib7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"2026012911211594200_bib8","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026012911211594200_bib9","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"2026012911211594200_bib10","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026012911211594200_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study [abstract]","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026012911211594200_bib12","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026012911211594200_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2026012911211594200_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026012911211594200_bib15","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41409-023-02016-1","article-title":"CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas","volume":"58","author":"Baur","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2026012911211594200_bib16","doi-asserted-by":"crossref","first-page":"e010687","DOI":"10.1136\/jitc-2024-010687","article-title":"Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Jin","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026012911211594200_bib17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.27526","article-title":"Clinical significance of complete remission and measurable residual disease in relapsed\/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy","volume":"100","author":"Zabaleta","year":"2025","journal-title":"Am J Hematol"},{"issue":"8","key":"2026012911211594200_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"2026012911211594200_bib19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic basis of relapse after GPRC5D-targeted CAR T cells","volume":"389","author":"Mi","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2026012911211594200_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.2024026622","article-title":"Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026012911211594200_bib21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2024-201356","article-title":"Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed\/refractory (RR) multiple myeloma (MM) [abstract]","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"issue":"suppl 16","key":"2026012911211594200_bib22","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1200\/JCO.2024.42.16_suppl.7511","article-title":"OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed\/refractory multiple myeloma: long term follow-up results of phase 1 study (POLARIS)","volume":"42","author":"Huang","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/5\/513\/2501309\/blood_bld-2025-030559-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/5\/513\/2501309\/blood_bld-2025-030559-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:21:25Z","timestamp":1769703685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/5\/513\/547852\/The-fully-human-anti-GPRC5D-CAR-T-cell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030559","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,29]]},"published":{"date-parts":[[2026,1,29]]}}}